WHAT IS CLAIMED IS:

1. An oral spray formulation for the treatment of pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction, comprising sildenafil base or a pharmaceutically acceptable salt thereof, wherein the pH of the formulation is about 1.5 to less than 3.0.

2. The oral spray formulation of claim 1, wherein the sildenafil base is present in an amount of about 7 to about 9 % w/v of the formulation.

3. The oral spray formulation of claim 2, wherein the sildenafil base is present in an amount of about 8.31 % w/v of the formulation.

4. The oral spray formulation of claim 1, wherein the sildenafil salt is present in an amount of about 10 to about 12 % w/v of the formulation.

5. The oral spray formulation of claim 4, wherein the sildenafil salt is present in an amount of about 11.67 % w/v of the formulation.

6. The oral spray formulation of claim 4 or claim 5, wherein the sildenafil salt is sildenafil citrate.

7. The oral spray formulation of claim 1, wherein the pH of the formulation is about 1.5 to less than 3.0.

8. The oral spray formulation of claim 1, wherein the formulation comprises a polar solvent.

9. The oral spray formulation of claim 8, wherein the polar solvent comprises propylene glycol and ethyl alcohol.

10. The oral spray formulation of claim 9, wherein the ratio of propylene glycol:ethyl alcohol is about 62.5:37.5 % v/v.

11. The oral spray formulation of claim 1, wherein the formulation comprises one or more pH-adjusting agents.

12. The oral spray formulation of claim 11, wherein the pH-adjusting agents may be acidifying agents, alkalizing agents or combinations thereof.

13. The oral spray formulation of claim 12, wherein the acidifying agent is hydrochloric acid (HCl).

14. The oral spray formulation of claim 13, wherein the HCl is present in an amount of about 10% v/v of the formulation.

15. The oral spray formulation of claim 12, wherein the alkalizing agent is sodium hydroxide (NaOH).

16. The oral spray formulation of claim 15, wherein the NaOH is present in an amount of about 2.1 % v/v of the formulation.

17. The oral spray formulation of claim 1, wherein the formulation comprises a taste-masking agent.

18. The oral spray formulation of claim 1, wherein the formulation comprises one or more pharmaceutically acceptable excipients, carriers or a combination thereof.

19. The oral spray formulation of claim 1, wherein the pH of the formulation is about 2.2 ± 0.5

20. The oral spray formulation of claim 19, wherein the pH of the formulation is about 2.2.

21. A method for the treatment of pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction, comprising administering to a patient an oral spray formulation comprising sildenafil base or a pharmaceutically acceptable salt thereof, wherein the pH of the formulation is about 1.5 to less than 3.0.

22. The method of claim 21, wherein the sildenafil base is present in an amount of about 7 to about 9 % w/v of the formulation.

23. The method of claim 22, wherein the sildenafil base is present in an amount of about 8.31 % w/v of the formulation.

24. The method of claim 21, wherein the sildenafil salt is present in an amount of about 10 to about 12 % w/v of the formulation.

25. The method of claim 24, wherein the sildenafil salt is present in an amount of about 11.67 % w/v of the formulation.

26. The method of claim 24 or claim 25, wherein the sildenafil salt is sildenafil citrate.

27. The method of claim 21, wherein the pH of the formulation is about 1.5 to less than 3.0.

28. The method of claim 21, wherein the formulation comprises a polar solvent.

29. The method of claim 28, wherein the polar solvent comprises propylene glycol and ethyl alcohol.

30. The method of claim 29, wherein the ratio of propylene glycol:ethyl alcohol is about 62.5:37.5 % v/v.

31. The method of claim 21, wherein the formulation comprises one or more pH-adjusting agents.

32. The method of claim 31, wherein the pH-adjusting agents may be acidifying agents, alkalizing agents or combinations thereof.

33. The method of claim 32, wherein the acidifying agent is HCl.

34. The method of claim 33, wherein the HCl is present in an amount of about 10 % v/v of the formulation.

35. The method of claim 32, wherein the alkalizing agent is NaOH.

36. The method of claim 35, wherein the NaOH is present in an amount of about 2.1 % v/v of the formulation.

37. The method of claim 21, wherein the formulation comprises a taste-masking agent.

38. The method of claim 21, wherein the formulation comprises one or more pharmaceutically acceptable excipients, carriers or a combination thereof.

39. The method of claim 21, wherein the pH of the formulation is about 2.2 ± 0.5

40. The method of claim 39, wherein the pH of the formulation is about 2.2.

41. The method of claim 21, wherein the amount of sildenafil administered per spray is 10 mg.

42. The method of claim 21, wherein the amount of sildenafil administered per spray is 20 mg.

43. The method of claim 21, wherein the amount of sildenafil administered per spray is 30 mg.

44. The method of claim 41, wherein the sildenafil exposure in the patient results in a ln-transformed dose-adjusted to 25 mg geometric mean AUC_{0-t}(ng-hr/mL) of approximately 299.36.

45. The method of claim 42, wherein the sildenafil exposure in the patient results in a ln-transformed dose-adjusted to 25 mg geometric mean AUC_{0-t}(ng-hr/mL) of approximately 323.16.

46. The method of claim 43, wherein the the sildenafil exposure in the patient results in a ln-transformed dose-adjusted to 25 mg geometric mean AUC_{0-t} (ng-hr/mL) of approximately 304.98.

47. The method of claim 41, wherein the sildenafil exposure in the patient results in a ln-transformed dose-adjusted to 25 mg geometric mean AUC_{0-inf}(ng-hr/mL) of approximately 310.60.

48. The method of claim 42, wherein the sildenafil exposure in the patient results in a ln-transformed dose-adjusted to 25 mg geometric mean AUC_{0-inf} (ng-hr/mL) of approximately 331.22.

49. The method of claim 43, wherein the sildenafil exposure in the patient results in a ln-transformed dose-adjusted to 25 mg geometric mean $AUC_{0\text{-}inf}$ (ng-hr/mL) of approximately 311.05.

50. The oral spray formulation of claim 1, wherein the amount of sildenafil administered per spray is 10 mg.

51. The oral spray formulation of claim 1, wherein the amount of sildenafil administered per spray is 20 mg.

52. The oral spray formulation of claim 1, wherein the amount of sildenafil administered per spray is 30 mg.

53. The oral spray formulation of claim 17, wherein the taste-masking agent comprises mint.

54. The oral spray formulation of claim 53, wherein the mint is peppermint or spearmint.

55. The oral spray formulation of claim 53 or claim 54, further comprising a fruit and/or chocolate flavor.

56. The method of claim 37, wherein the taste-masking agent comprises mint.

57. The method of claim 53, wherein the mint is peppermint or spearmint.

58. The method of claim 53 or claim 54, further comprising a fruit and/or chocolate flavor.

59. The oral spray formulation of claim 53, further comprising a sweetener.

60. The oral spray formulation of claim 59, wherein the sweetener is sucralose.

61. The method of claim 55, further comprising a sweetener.

62. The method of claim 61, wherein the sweetener is sucralose.

CLAIMS

1. An oral spray formulation for the treatment of pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction, comprising sildenafil base or a pharmaceutically acceptable salt thereof, in which the pH of the formulation is about 1.5 to less than 3.0.

2. Use of sildenafil in the preparation of a medicament for the treatment of pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction, in which the medicament comprises an oral spray formulation comprising sildenafil base or a pharmaceutically acceptable salt thereof, in which the pH of the formulation is about 1.5 to less than 3.0.

3. An oral spray formulation according to Claim 1 or a use according to Claim 2, in which the sildenafil base is present in an amount of about 7 to about 9 % w/v of the formulation.

4. An oral spray formulation or use according to Claim 3, in which the sildenafil base is present in an amount of about 8.31 % w/v of the formulation.

5. An oral spray formulation according to Claim 1 or a use according to Claim 2, in which the sildenafil salt is present in an amount of about 10 to about 12 % w/v of the formulation.

6. An oral spray formulation or use according to Claim 5, in which the sildenafil salt is present in an amount of about 11.67 % w/v of the formulation.

7. An oral spray formulation according to Claim 1 or a use according to Claim 2, in which the sildenafil salt is sildenafil citrate.

8. An oral spray formulation according to Claim 1 or a use according to Claim 2, in which the formulation comprises a polar solvent.

9. An oral spray formulation or use according to Claim 8, in which the polar solvent comprises propylene glycol and ethyl alcohol.

10. An oral spray formulation or use according to Claim 9, in which the ratio of propylene glycokethyl alcohol is about 62.5:37.5 % v/v.

11. An oral spray formulation according to Claim 1 or a use according to Claim 2, in which the formulation comprises one or more pH- adjusting agents.

12. An oral spray formulation or use according to Claim 11, in which the pH-adjusting agents are acidifying agents, alkalizing agents or combinations thereof.

13. An oral spray formulation or use according to Claim 12, in which the acidifying agent is HCl.

14. An oral spray formulation or use according to Claim 13, in which the HCl is present in an amount of about 10 % v/v of the formulation.

15. The oral spray formulation or use according to Claim 12, in which the alkalizing agent is NaOH.

16. An oral spray formulation or use according to Claim 15, in which the NaOH is present in an amount of about 2.1 % v/v of the formulation.

17. An oral spray formulation according to Claim 1 or a use according to Claim 2, in which the formulation further comprises a taste-masking agent and/or a flavour.

18. An oral spray formulation according to Claim 1 or a use according to Claim 2, in which the formulation comprises one or more pharmaceutically acceptable excipients, carriers or a combination thereof.

19. An oral spray formulation according to Claim 1 or a use according to Claim 2, in which the pH of the formulation is about 2.2 +- 0.5

20. An oral spray formulation according to Claim 1 or a use according to Claim 2, in which the amount of sildenafil administered per spray is between 10 mg and 30 mg.

21. An oral spray formulation or use according to Claim 20, in which the sildenafil exposure in the patient results in a ln-transformed dose-adjusted to 25 mg geometric mean AUC_{0-t}(ng-hr/mL) of approximately 299.36, 323.16 or 304.98.

22. An oral spray formulation or use according to Claim 20, in which the sildenafil exposure in the patient results in a ln-transformed dose-adjusted to 25 mg geometric mean AUC_{0-inf}(ng-hr/mL) of approximately 310.60, 331.22 or 311.05.

23. An oral spray formulation according to Claim 1 or a use according to Claim 2, further comprising a sweetener.

24. An oral spray formulation or use according to Claim 23, in which the sweetener is sucralose.

25. An oral spray formulation or use according to Claim 17 in which the taste-masking agent is chosen from the list comprising: mint; and the flavour is chosen from the list comprising: a fruit and/or chocolate flavour.